Literature DB >> 24973347

Psoriasis induced by thalidomide in a patient with multiple myeloma.

Anna Ferrazzi1, Renato Zambello2, Irene Russo1, Mauro Alaibac1.   

Abstract

A 54-year-old woman developed psoriasis on the plantar surface of her feet after 2 weeks of thalidomide 100 mg daily for the treatment of multiple IgG myeloma. She did not have any previous history of psoriasis. Thalidomide was immediately stopped and topical treatment with calcipotriol ointment and β-methasone valerate was started. Psoriasis disappeared completely after 2 weeks of topical therapy. This is the first case of de novo psoriasis in a patient with multiple myeloma under treatment with thalidomide. Our observation provides further evidence of the potential paradoxical effect of thalidomide on tumour necrosis factor-α production. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24973347      PMCID： PMC4078429          DOI： 10.1136/bcr-2014-204469

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  9 in total

1.  Exacerbation of psoriasis by thalidomide in Behçet's syndrome.

Authors:  C M Dobson; R A Parslew
Journal:  Br J Dermatol       Date:  2003-08       Impact factor: 9.302

2.  Thalidomide in the treatment of psoriasis vulgaris: a pilot study.

Authors:  Li Li; Fei Su; Hongzhong Jin
Journal:  J Dermatol       Date:  2011-10-31       Impact factor: 4.005

3.  Exacerbation of psoriasis by thalidomide in a patient with erythema multiforme.

Authors:  K Varma; A Y Finlay
Journal:  Br J Dermatol       Date:  2006-04       Impact factor: 9.302

4.  Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

Authors:  J B Marriott; I A Clarke; K Dredge; G Muller; D Stirling; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

5.  Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells.

Authors:  Jan Komorowski; Hanna Jerczyńska; Agnieszka Siejka; Patrycja Barańska; Hanna Ławnicka; Zofia Pawłowska; Henryk Stepień
Journal:  Life Sci       Date:  2005-11-28       Impact factor: 5.037

Review 6.  Novel therapies for psoriasis.

Authors:  Jennifer Cather; Alan Menter
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

Review 7.  Thalidomide: a new anticancer drug?

Authors:  Massimo Fanelli; Roberta Sarmiento; Domenico Gattuso; Guido Carillio; Barbara Capaccetti; Angelo Vacca; Aldo Maria Roccaro; Giampietro Gasparini
Journal:  Expert Opin Investig Drugs       Date:  2003-07       Impact factor: 6.206

Review 8.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Authors:  Uwe Wollina; Gesina Hansel; André Koch; Jaqueline Schönlebe; Erich Köstler; Gunter Haroske
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

9.  Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.

Authors:  S Maïga; P Gomez-Bougie; S Bonnaud; C Gratas; P Moreau; S Le Gouill; C Pellat-Deceunynck; M Amiot
Journal:  Br J Cancer       Date:  2013-04-30       Impact factor: 7.640
  9 in total
  1 in total

1.  Development of Drug-Induced Inverse Psoriasis in a Patient with Crohn's Disease.

Authors:  Evan Darwin; Amar Deshpande; Hadar Lev-Tov
Journal:  ACG Case Rep J       Date:  2018-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.